GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » General and Admin. Expense

IRLAB Therapeutics AB (OSTO:IRLAB A) General and Admin. Expense : kr38.74 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. IRLAB Therapeutics AB's General and Admin. Expense for the three months ended in Mar. 2024 was kr0.00 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 was kr38.74 Mil.


IRLAB Therapeutics AB General and Admin. Expense Historical Data

The historical data trend for IRLAB Therapeutics AB's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB General and Admin. Expense Chart

IRLAB Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.16 65.63 81.74 125.91 -

IRLAB Therapeutics AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.13 38.74 - - -

IRLAB Therapeutics AB General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr38.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IRLAB Therapeutics AB General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Traded in Other Exchanges
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines